Basophil granule proteins
AssigneesIncyte Pharmaceuticals, Inc., Mayo Foundation for Medical Education and Research
InventorsRandy W. Scott, Gerald J. Gleich, Craig G. Wilde
Life of this patent
Estimating the term…
Abstract
Several natural polypeptides (basophil granule proteins, "BGP") derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.
Claims4
An isolated and purified basophil protein (BGP) wherein the BGP has an N-terminal sequence described by a sequence selected from the group consisting of:
- Asp-Ile-Gly-Pro-Asp-Gln-His-Thr-Ser-Arg-Pro-Trp-Gly-Gln-Thr (SEQ. ID NO. 1);
- Asp-Val-Lys-Lys-Asp-Met-Glu-Val-Ser-Cys-Pro-Asp-Gly-Tyr-Thr
- (SEQ. ID NO. 2);
- Val-Met-X-Pro-Asp-Ala-Arg-Ser-X-Arg-Pro-Asp-Gly-X-Thr
- ( SEQ. ID NO. 3 );
- Ala-Ile-Tyr-X-Arg-Ile-Pro-X-X-Ile-Ala-Gly-Glu-Phe-Arg-Tyr-Gly-Thr-Val-Tyr-T yr-Gln-Gly-Ser-Leu (SEQ. ID NO. 4);
- Asp-Ile-Pro-Glu-Val-X-Val-X-Leu-Ala-Ala-Asp-Glu-Ser-Leu-Ala-Pro-Lys (SEQ. ID NO. 5);
- Tyr-Pro-Gln-Leu-Ala-Ile-Asn (SEQ. ID NO. 6);
- Ser-Ile-Gly-Phe-Val-Glu-Val-X-Leu-Val-Leu (SEQ. ID NO. 7);
- Ala-Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr-Thr-Cys-Ile (SEQ. ID NO. 8);
- Ala-Pro-Ala-Leu-Thr-Ile-Ser-Asn-Gln (SEQ. ID NO. 9);
- Asp-Ile-Gly-Pro-Asp-Gln-His-Thr-Ser-X.sub.1 -Pro-X.sub.2 -Gly-Gln-Thr-Arg-X-Pro-Gln-Leu-Thr-Gly-Gly-Glu-Ala-X-Val (SEQ. ID NO. 10);
- Arg-Asp-Val-Pro-Pro-Asp-X-Val-Val-Ser-X-Pro-Ser-Ser-Asp-Thr (SEQ. ID NO. 11);
- Gly-Pro-Pro-Thr-Phe-Asn-Lys-Ile-Thr-Pro-Asn-Asp-Ala-Asp-Phe (SEQ. ID NO. 14);
- Ala-Ile-Gln-Cys-Pro-X.sub.3 -Ser-Gln-Phe-X.sub.4 -X.sub.5 -Pro-X.sub.6 -Phe-Leu-Ala-Thr-Gly-Val-Met (SEQ. ID NO. 15 );
- Asp-Ile-Pro-Glu-Val-Cys-Phe-Asn (SEQ. ID NO. 16);
- Asp-Pro-Gly-Glu-Val-Lys-Ala-Leu-Pro-Met-Gln (SEQ. ID NO. 17);
- Lys-Pro-Gln-Met-Phe-Thr-Ile-X-Gln-Asn-X-Ala-Thr-Trp-Met (SEQ. ID NO. 18);
- Lys-Ile-Gly-Gly-Phe-Glu-Val-Thr-Asp-Val-Phe-Ala-Pro-Val-Met-Ala (SEQ. ID NO. 19);
- Ile-Leu-Gly-Val-Phe-X-Val-Glu-Gln-X-Phe-Ser-Phe-X-Leu (SEQ. ID NO. 20);
- Asp-Pro-Pro-Thr-Phe-Asn-Lys-Ile-Thr-Pro-Asn-Leu-Leu-Glu-Phe-Ala-Asp-Gly-Leu -Tyr-Lys-Gln-Glu (SEQ. ID NO. 21);
- and
- Ser-Glu-Leu-Thr-Lys-Met-Asn-Gln-Arg-Ser-Phe (SEQ. ID NO. 22);
- where each X, X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5 and X.sub.6 independently represents a variable amino acid residue.
Dependencies are inferred from the claim text.